OraSure Technologies (NASDAQ:OSUR - Get Free Report) posted its earnings results on Wednesday. The medical instruments supplier reported $0.04 EPS for the quarter, hitting the consensus estimate of $0.04, Briefing.com reports. The company had revenue of $54.10 million during the quarter, compared to the consensus estimate of $52.27 million. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The firm's revenue for the quarter was down 65.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.37 earnings per share. OraSure Technologies updated its Q2 2024 guidance to EPS.
OraSure Technologies Stock Performance
Shares of NASDAQ OSUR traded down $0.26 during trading hours on Thursday, hitting $5.05. The company's stock had a trading volume of 1,166,201 shares, compared to its average volume of 870,201. OraSure Technologies has a 12 month low of $4.38 and a 12 month high of $8.45. The business has a 50-day simple moving average of $6.03 and a 200-day simple moving average of $6.79. The stock has a market cap of $385.99 million, a price-to-earnings ratio of 7.01 and a beta of 0.23.
Analysts Set New Price Targets
OSUR has been the subject of several analyst reports. StockNews.com upgraded shares of OraSure Technologies from a "hold" rating to a "buy" rating in a research note on Wednesday, May 1st. Evercore ISI lowered their target price on shares of OraSure Technologies from $7.00 to $6.50 and set an "in-line" rating on the stock in a report on Thursday, April 4th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, OraSure Technologies currently has a consensus rating of "Moderate Buy" and a consensus target price of $6.38.
View Our Latest Analysis on OraSure Technologies
About OraSure Technologies
(
Get Free Report)
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
See Also
Before you consider OraSure Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OraSure Technologies wasn't on the list.
While OraSure Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
